Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma
NCT03056599 is a phase 1 interventional trial sponsored by Presage Biosciences. As of 21 Nov 2026, it is completed. It studies Multiple drug microinjection in Soft Tissue Sarcoma Adult. The registry lists an enrollment of 23 participants at 3 sites in 1 country. The registry lists a start date of 15 Dec 2016 and a primary completion date of 22 Jul 2021. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT03056599 |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | Presage Biosciences |
| Enrollment | 23 |
| Registered sites | 3 |
| Countries | 1 |
| Conditions | Soft Tissue Sarcoma Adult |
| Drugs | Multiple drug microinjection |
| Start | 15 Dec 2016 |
| Primary completion | 22 Jul 2021 |
| Study completion | 22 Sept 2021 |
| Last update posted | 24 Sept 2021 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Gary Deutsch, MD
Northwell Health
Principal Investigator - Kenneth Gundle, MD
Oregon Health & Science University (OHSU)
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Monter Cancer Center (northwell Health)
Lake Success
- Ohsu Knight Cancer Institute
Portland
- Fred Hutchinson Cancer Research Center/seattle Cancer Care Alliance (scca)/university of Washington
Seattle
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT03056599
Each answer restates registry values shown on this page.
What is NCT03056599?
NCT03056599 is a phase 1 interventional trial sponsored by Presage Biosciences. It studies Multiple drug microinjection in Soft Tissue Sarcoma Adult.
Who leads NCT03056599?
The registry names Gary Deutsch, MD (principal investigator, Northwell Health), Kenneth Gundle, MD (principal investigator, Oregon Health & Science University (OHSU)) and Seth Pollack, MD (principal investigator, Fred Hutchinson Cancer Research Center/SCCA) as overall officials.
Where does NCT03056599 run?
The registry lists 3 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT03056599 study?
The registered drug and biological interventions are Multiple drug microinjection.
When did NCT03056599 end?
The registry lists a primary completion date of 22 Jul 2021 and a study completion date of 22 Sept 2021. The sponsor last updated the record on 24 Sept 2021.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.